BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32547188)

  • 1. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study.
    Subramanian S; Prasanna R; Biswas G; Das Majumdar SK; Joshi N; Bunger D; Khan MA; Ahmad I
    Breast Cancer (Dove Med Press); 2020; 12():77-85. PubMed ID: 32547188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study.
    Narayanan P; Dattatreya PS; Prasanna R; Subramanian S; Jain K; Somanath NS; Joshi N; Bunger D; Khan MA; Chaturvedi A; Ahmad I
    Sarcoma; 2019; 2019():3158590. PubMed ID: 31827370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.
    Subramanian S; Majumdar SKD; Biswas G; Joshi N; Bunger D; Khan MA; Ahmad I
    Mol Clin Oncol; 2020 Sep; 13(3):14. PubMed ID: 32754328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study.
    Kumar Das Majumdar S; Subramanian S; Biswas G; Joshi N; Khan MA; Ahmad I
    Oncol Lett; 2020 Dec; 20(6):344. PubMed ID: 33123255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer.
    Badiginchala R; Dattatreya PS; Suresh AVS; Nirni SS; Andra VV; Bunger D; Chaturvedi A
    Onco Targets Ther; 2023; 16():215-225. PubMed ID: 37033671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.
    Subramanian S; Samar A; Joshi N; Sejpal J; Khan MA; Ahmad I
    Mol Clin Oncol; 2021 Aug; 15(2):162. PubMed ID: 34194740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer.
    Samar A; Tiwari S; Subramanian S; Joshi N; Sejpal J; Khan MA; Ahmad I
    Prostate Cancer; 2020; 2020():4242989. PubMed ID: 33381320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series.
    Tiwari S; Bisaria A; Kaur H; Joshi N; Sejpal J; Khan MA
    J Oncol Pharm Pract; 2021 Dec; 27(8):2030-2034. PubMed ID: 33853469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.
    Ramaswamy R; Joshi N; Khan MA; Siddhara S
    Onco Targets Ther; 2019; 12():5679-5685. PubMed ID: 31406465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.
    Ahmad A; Sheikh S; Taran R; Srivastav SP; Prasad K; Rajappa SJ; Kumar V; Gopichand M; Paithankar M; Sharma M; Rane RC; Ahmad I
    Clin Breast Cancer; 2014 Jun; 14(3):177-81. PubMed ID: 24287370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.
    McKeage K
    Clin Drug Investig; 2017 Apr; 37(4):405-410. PubMed ID: 28255844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery.
    Gupta S; Pawar SS; Bunger D
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29133580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report.
    Prasanna R; Bunger D; Khan MA
    Mol Clin Oncol; 2018 Feb; 8(2):296-299. PubMed ID: 29435291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.